NCT06643390View on ClinicalTrials.gov

A Study of MK-2225 in Healthy Participants (MK-2225-003)

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 21, 2023

Primary Completion Date

July 14, 2025

Study Completion Date

July 14, 2025

Conditions
Systemic Sclerosis
Interventions
DRUG

MK-2225

Subcutaneous administration

OTHER

Placebo

Subcutaneous administration

Trial Locations (2)

65802

Bio-Kinetic Clinical Applications, LLC dba QPS-MO (Site 0004), Springfield

33014-3616

Clinical Pharmacology of Miami (Site 0002), Miami

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06643390 - A Study of MK-2225 in Healthy Participants (MK-2225-003) | Biotech Hunter | Biotech Hunter